ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › CXCL9
Chemokine

CXCL9

The first-identified CXCR3 ligand—an IFN-γ-induced chemokine that recruits CD8+ T cells into the tumor immune microenvironment.

View
Definition
CXCL9 (Monokine Induced by Gamma-Interferon, MIG) is a CXC chemokine secreted by tumor cells and immune cells in response to IFN-γ stimulation. It binds CXCR3 on CD8+ T cells, driving their migration into the tumor immune microenvironmentLoading.... Together with CXCL10Loading... and CXCL11Loading..., these three ligands form the CXCR3 chemokine axis—a critical pathway determining whether tumors are immunologically "hot" or "cold."
IFN-γ Induced
Expression driven by interferon-gamma signaling
CXCR3 Ligand
Binds CXCR3 receptor on effector T cells
TiME Recruitment
Drives CD8+ T cell infiltration into tumors
Hot vs Cold Indicator
Distinguishes inflamed from immune-desert tumors

The CXCR3 Chemokine Axis

CXCL9, CXCL10Loading..., and CXCL11Loading... are three structurally related IFN-γ-inducible chemokines that all bind CXCR3 on effector T cells. Though they share a receptor, each has distinct properties:

  • CXCL9: Most selectively IFN-γ-dependent; primarily T cell chemoattractant
  • CXCL10Loading...: Dual function—T cell recruitment plus angiostatic activity
  • CXCL11Loading...: Highest CXCR3 affinity; also signals through CXCR7

The relative expression of these three chemokines in the TiMELoading... reflects the strength and character of the local immune response.

Simplified

Three Chemokines, One Receptor: CXCL9, CXCL10, and CXCL11 all attract T cells to tumors through the CXCR3 receptor. Each has unique properties, but together they determine whether a tumor is "hot" (T cell-infiltrated) or "cold" (immune-excluded).

T Cell Recruitment to the TiME

CXCL9's primary role in cancer biology is establishing the chemokine gradient that recruits CXCR3+ effector T cells into tumors. This process is critical because even patients who generate tumor-specific T cells may fail immunotherapy if those T cells cannot physically reach the tumor.

In the TiMELoading..., CXCL9 is produced primarily by myeloid cells and tumor cells in response to IFN-γ from early-arriving immune cells. This creates a positive feedback loop: initial T cell infiltration produces IFN-γ, which induces CXCL9, which recruits additional T cells.

Simplified

Why It Matters: Having T cells that can recognize a tumor isn't enough—those T cells must physically enter the tumor. CXCL9 creates the "come here" signal that guides them in.

Positive Feedback: T cells produce IFN-γ → IFN-γ induces CXCL9 → CXCL9 recruits more T cells.

Biomarker Applications

CXCL9 expression in tumor tissue serves as a proxy for T cell-inflamed status. High CXCL9 correlates with:

However, in HR+ breast cancerLoading..., Napolitano et al. (2026) demonstrated that high CXCR3 ligand expression correlated with shorter relapse-free survival in endocrine-treated patients—revealing a context-dependent, paradoxical role where these "immune-recruiting" chemokines may also promote tumor cell proliferation.

Simplified

General Pattern: High CXCL9 = more T cells in the tumor = better immunotherapy response.

The Paradox: In hormone receptor-positive breast cancer, high CXCL9 and its sister chemokines predicted worse outcomes on endocrine therapy (Napolitano et al., 2026)—suggesting these chemokines may have direct effects on tumor cells beyond immune recruitment.

Simple Recruitment Signal
Chemokines like CXCL9 are passive directional cues—their presence simply attracts immune cells to a location.
Context-Dependent Functional Mediator
CXCR3 ligands have direct effects on tumor cells and context-dependent pro- or anti-tumor roles, measurable by spatial proteomics approaches.

Clinical Significance

  • Immunotherapy biomarker: High CXCL9 expression indicates T cell-inflamed TiMELoading..., predicting ICILoading... response across tumor types
  • HR+ breast cancer: High CXCR3 ligand expression correlated with shorter RFS in endocrine-treated patients (Napolitano et al., J Clin Invest. 2026;136(3):e188458)
  • Hot vs cold tumors: CXCL9 is among the most reliable discriminators of inflamed versus immune-desert phenotypes
  • Combination strategies: Inducing CXCL9 expression in cold tumors is an active area of therapeutic development

Connected Terms

Share This Term
Term Connections